TMCnet News

Research and Markets: Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles
[September 23, 2015]

Research and Markets: Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/g2m9cn/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development (Partial List)

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ADC (News - Alert) Therapeutics Sarl
  • Affimed Therapeutics AG
  • Aptose Biosciences Inc.
  • Arbutus Biopharma Corporation
  • AVEO Pharmaceuticals, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Biogenomics Limited
  • Bristol-Myers Squibb Company
  • Celgene Corporation
    • Cell Medica Limited
  • Cellular Biomedicine Group, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Curis, Inc.
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • Molecular Templates Inc.
  • NantKwest, Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Philogen S.p.A.
  • Seattle Genetics, Inc.
  • Selvita SA
  • Sigma-Tau S.p.A.
  • TG Therapeutics, Inc.
  • Theravectys SA


Drug Profiles (Partial List)

  • abexinostat hydrochloride - Drug Profile
  • acalisib - Drug Profile
  • ADCT-301 - Drug Profile
  • AFM-13 - Drug Profile
  • Alocrest - Drug Profile
  • aNK Program - Drug Profile
  • APTO-253 - Drug Profile
  • azacitidine - Drug Profile
  • BMS-986016 - Drug Profile
  • BPX-501 - Drug Profile
  • brentuximab vedotin - Drug Profile
  • CBM-C30.1 - Drug Profile
  • Cell Therapy to Target (News - Alert) CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
  • Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile
  • Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
  • Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
  • Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile
  • CMD-003 - Drug Profile
  • CPI-0610 - Drug Profile
  • CUDC-907 - Drug Profile
  • Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile
  • INCB-40093 - Drug Profile
  • Indimitecan - Drug Profile
  • Indotecan hydrochloride - Drug Profile
  • interferon alfa-2b (recombinant) - Drug Profile
  • Iomab-B - Drug Profile
  • NSC-678515 - Drug Profile
  • panobinostat - Drug Profile
  • pembrolizumab - Drug Profile
  • pevonedistat hydrochloride - Drug Profile
  • procarbazine hydrochloride - Drug Profile
  • radretumab - Drug Profile
  • Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile
  • TGR-1202 - Drug Profile
  • TKM-PLK1 - Drug Profile

For more information visit http://www.researchandmarkets.com/research/g2m9cn/hodgkin_lymphoma



[ Back To TMCnet.com's Homepage ]